Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Imunomodulatorji pri zdravljenju malignega melanoma
Avtorji:Mesti, Tanja (Avtor)
Boc, Marko (Avtor)
Reberšek, Martina (Avtor)
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Ključne besede:imunomodulatorji, melanomi, maligni melanomi, zdravljenje
Leto izida:2013
UDK:616.5
ISSN pri članku:1408-1741
OceCobissID:65324032 Povezava se odpre v novem oknu
URN:URN:NBN:SI:doc-KP3JBJ3R
COBISS_ID:1682043 Povezava se odpre v novem oknu
Število ogledov:1234
Število prenosov:271
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (362,34 KB)
 
Nadgradivo:Onkologija
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:by Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Imunomodulators in the treatment of malignant melanoma - case report
Povzetek:The incidence of melanoma is increasing, both in Slovenia and world-wide, more than any other form of cancer. According to the Cancer Registry of Slovenia, 415 patients were diagnosed with this disease in 2009 (1). Surgical removal of skin melanoma is the primary curative treatment for patients with early-stage disease. There are approximately 80% of such patients. In high-risk patients (around 10%), we also recommend treatment with high doses of interferon-α2b (2, 3). Metastatic melanoma is still an incurable disease with a 5-year survival of less than 5%. However, the prognosis for these patients has improved in the last few years, thanks to new developments in the field of systemic treatment. Besides standard treatment with systemic chemotherapy, new registered medicines are now also available with a different mechanism of action than chemotherapy, such as immunotherapy with the monoclonal antibody ipilimumab, BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitors (2, 3).

Arhiv

niGradiv

Nazaj